Skip to content
value.today
Mesa Laboratories, Inc. logo

Mesa Laboratories, Inc.

MLAB
$726 Mmarket cap on Oct 28, 2026+33.8% since Jan 2024
1M
-2.8%
Compare
World rank
#10,912
Revenue
$249 M
For year ending March-2026
Net income
$7 M
2.7% margin
SEC filing
Employees
347
As on June-2020
value.today research

Mesa Laboratories, Inc. in brief

Mesa Laboratories, Inc. is a listed company in the Scientific Technical Instruments industry, based in Lakewood, Colorado, USA. Its market value was $726 M on 28 October 2026, which makes it the 10,912th largest listed company in the world and the 2,268th largest in the USA on this site. In the year to March 2026 it had sales of $249 M and a net profit of $7 M, about 3 cents of profit for every dollar of sales. It employs about 347 people and Siddhartha Kadia is its chief executive. Its largest product and service lines by sales in 2026 were Consumables (59%) and Hardware and Software (23%). By market, the largest shares of its 2026 sales came from USA (47%) and China (8%). Its shares trade under the symbol MLAB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Mesa Laboratories, Inc.

Mesa Laboratories Develops, Manufactures and Markets, high quality process validation and monitoring instruments and consumables company. The company products are used to assure product quality, control manufacturing processes and to solve problems in niche markets in healthcare, industrial, pharmaceutical, medical and food processing applications. The headquarters is in USA.

Mesa Laboratories, Inc. timeline

3 events, 1995–2025
  1. 1995
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 💰
    Record revenue of $249 million
    FY2025, the highest of the 8 years on record.
  5. 💰
    Record net income of $7 million
    FY2025, the highest profit of the 4 years on record.

Events of Mesa Laboratories, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$431 M$862 M$1.3 B$1.7 B2020202120222023202420252026

World rank over time

▼ down 3,665 places since 2020
2020-01-01: #7267#7,26720202021-01-01: #6485#6,48520212022-01-07: #7195#7,19520222022-12-25: #9127#9,12720222023-07-30: #10766#10,76620232024-01-05: #12094#12,09420242026-03-08: #7132#7,13220262026-08-01: #11585#11,58520262026-09-24: #10805#10,80520262026-10-28: #10932#10,9322026

Rank in USA: #1,996 (Jan 2020) · #1,872 (Jan 2021) · #2,063 (Jan 2022) · #2,123 (Dec 2022) · #2,406 (Jul 2023) · #2,466 (Jan 2024) · #1,254 (Mar 2026) · #2,433 (Aug 2026) · #2,262 (Sep 2026) · #2,270 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
109.1×
Price / sales (TTM)
2.9×
Price / book
3.9×
Free cash flow yield
5.4%
Net margin (TTM)
2.6%
Operating margin
7.4%
Return on equity
3.6%
Liabilities / assets
56.5%
Net debt
$41M
Payout ratio
52.9%
Revenue growth
+3.4%
R&D / revenue
8.2%
Revenue per employee
$718 K
Profit per employee
$19 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2019: revenue $103M, net income —$103MFY19Fiscal year ending Mar 2020: revenue $118M, net income —$118MFY20Fiscal year ending Mar 2021: revenue $134M, net income $3M$134MFY21Fiscal year ending Mar 2022: revenue $184M, net income $2M$184MFY22Fiscal year ending Mar 2023: revenue $219M, net income $1M$219MFY23Fiscal year ending Mar 2024: revenue $216M, net income $-254M$216MFY24Fiscal year ending Mar 2025: revenue $241M, net income $-2M$241MFY25Fiscal year ending Mar 2026: revenue $249M, net income $7M$249MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026$249M+3.4%$19M$7M2.7%
Mar 2025$241M+11.5%$16M$-2M-0.8%
Mar 2024$216M-1.3%$-272M$-254M-117.6%
Mar 2023$219M+18.8%$3M$1M0.4%
Mar 2022$184M+37.6%$5M$2M1.0%
Mar 2021$134M+13.8%$12M$3M2.4%
Mar 2020$118M+14.1%$8M——
Mar 2019$103M—$10M——

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$43M$3M$40M$1.21$0.64
Mar 2025$47M$4M$43M$-0.36$0.64
Mar 2024$44M$3M$42M$-47.20$0.64
Mar 2023$28M$5M$23M$0.17$0.64
Mar 2022$39M$4M$35M$0.35$0.64
Mar 2021$37M$2M$35M$0.64$0.64
Mar 2020$27M$2M$25M$0.41$0.64
Mar 2019$31M$1M$29M$1.86$0.64

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$251M
Net income, trailing 12 months
$7M
RevenueNet income
Three months to Dec 2024: revenue $63M, net income $-2M$63MDec ’24Three months to Mar 2025 (from the annual report): revenue $62M, net income $-7M$62MMar ’25Three months to Jun 2025: revenue $60M, net income $5M$60MJun ’25Three months to Sep 2025: revenue $61M, net income $2M$61MSep ’25Three months to Dec 2025: revenue $65M, net income $4M$65MDec ’25Three months to Mar 2026 (from the annual report): revenue $64M, net income $-4M$64MMar ’26Three months to Jun 2026: revenue $60M, net income $3M$60MJun ’26Three months to Sep 2026: revenue $62M, net income $4M$62MSep ’26

Latest quarter to Sep 2026: revenue $62M (+2.6% on a year earlier), net income $4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Mesa Laboratories, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$249 M
Operating income
$19 M
Net income
$7 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$428 M
Total liabilities
$242 M
Total equity
$186 M

As of March-2026

Top 100 institutional investors in Mesa Laboratories, Inc.#

As of Sep 30, 2026
184 institutions held 5.6 M shares (about 99.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 47.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Mesa Laboratories, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Long Path Partners LP480,169+3,043 (+0.64%)8.54%$62 MNov 16, 2026
2BlackRock, Inc.457,599+17,047 (+3.87%)8.14%$59 MNov 13, 2026
3Wasatch Advisors LP387,129+271,461 (+234.69%)6.89%$50 MOct 13, 2026
4Victory Capital Management Inc276,565New4.92%$36 MNov 10, 2026
5Vanguard Capital Management LLC236,214-1,243 (-0.52%)4.20%$31 MNov 13, 2026
6Raymond James Financial Inc175,079+25,142 (+16.77%)3.12%$23 MNov 12, 2026
7Arrowstreet Capital, Limited Partnership173,231New3.08%$23 MNov 13, 2026
8Geode Capital Management, LLC165,736+26,054 (+18.65%)2.95%$22 MNov 6, 2026
9Dimensional Fund Advisors LP163,907+15,512 (+10.45%)2.92%$21 MNov 4, 2026
10Jacobs Levy Equity Management, Inc145,570+14,732 (+11.26%)2.59%$19 MNov 16, 2026
11Kennedy Capital Management LLC143,200+4,899 (+3.54%)2.55%$19 MNov 13, 2026
12Morgan Stanley140,015-16,964 (-10.81%)2.49%$18 MNov 13, 2026
13State Street Corp135,509+11,217 (+9.02%)2.41%$18 MNov 12, 2026
14Ranger Investment Management, L.P.131,431-42,557 (-24.46%)2.34%$17 MNov 6, 2026
15William Blair Investment Management, LLC130,323New2.32%$17 MNov 6, 2026
16Diamond Hill Capital Management, LLC (Investment Advisor)130,173-25,598 (-16.43%)2.32%$17 MNov 10, 2026
17AQR Capital Management LLC129,111-74,628 (-36.63%)2.30%$17 MNov 16, 2026
18D. E. Shaw & Co., Inc.127,505+45,750 (+55.96%)2.27%$17 MNov 16, 2026
19Two Sigma Investments, LP119,478+90,239 (+308.63%)2.13%$16 MNov 16, 2026
20Topline Capital Management, LLC95,499+93,125 (+3922.70%)1.70%$12 MNov 16, 2026
21Crawford Investment Counsel Inc90,060-8,745 (-8.85%)1.60%$12 MNov 16, 2026
22Jane Street Group, LLC85,367+13,787 (+19.26%)1.52%$11 MNov 12, 2026
23Vanguard Portfolio Management LLC84,065+14,715 (+21.22%)1.50%$11 MNov 13, 2026
24Russell Investments Group, Ltd.71,823-50,022 (-41.05%)1.28%$9 MNov 6, 2026
25Northern Trust Corp67,078+1,333 (+2.03%)1.19%$9 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Mesa Laboratories, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Meros Investment Management, LP62,594-5,368 (-7.90%)1.11%$8 MNov 17, 2026
27Gabelli Funds LLC62,475-24 (-0.04%)1.11%$8 MNov 12, 2026
28FMR LLC61,238-27,619 (-31.08%)1.09%$8 MNov 10, 2026
29Charles Schwab Investment Management Inc52,115-2,348 (-4.31%)0.93%$7 MNov 16, 2026
30Bank of New York Mellon Corp45,458-144 (-0.32%)0.81%$6 MNov 5, 2026
31Goldman Sachs Group Inc45,192-19,130 (-29.74%)0.80%$6 MNov 16, 2026
32Royce & Associates LP39,598-73,797 (-65.08%)0.70%$5 MNov 9, 2026
33Vanguard Fiduciary Trust Co39,354-182 (-0.46%)0.70%$5 MNov 13, 2026
34Man Group plc33,404+9,334 (+38.78%)0.59%$4 MNov 16, 2026
35Janus Henderson Group Ltd.31,869—0.57%$4 MNov 16, 2026
36Principal Financial Group Inc30,421+18,352 (+152.06%)0.54%$4 MNov 2, 2026
37Aberdeen Group plc26,005New0.46%$3 MNov 10, 2026
38XTX Topco Ltd25,979+8,504 (+48.66%)0.46%$3 MNov 16, 2026
39BBR Partners, LLC25,1950 (0.00%)0.45%$3 MNov 16, 2026
40American Century Companies Inc23,532+3,168 (+15.56%)0.42%$3 MNov 12, 2026
41HRT Financial LP22,249New0.40%$3 MNov 13, 2026
42Quadrature Capital Ltd21,886+14,204 (+184.90%)0.39%$3 MNov 13, 2026
43Bank Of America Corp /de/20,901-29,051 (-58.16%)0.37%$3 MNov 16, 2026
44State Of Wisconsin Investment Board19,630+724 (+3.83%)0.35%$3 MNov 16, 2026
45Rice Hall James & Associates, LLC19,135+167 (+0.88%)0.34%$2 MNov 16, 2026
46Qube Research & Technologies Ltd18,704-18,698 (-49.99%)0.33%$2 MNov 13, 2026
47Segall Bryant & Hamill, LLC18,139+31 (+0.17%)0.32%$2 MNov 16, 2026
48Ameriprise Financial Inc18,056New0.32%$2 MNov 16, 2026
49King Luther Capital Management Corp17,4110 (0.00%)0.31%$2 MNov 5, 2026
50Los Angeles Capital Management LLC15,875+8,487 (+114.88%)0.28%$2 MNov 12, 2026
51Public Sector Pension Investment Board15,605New0.28%$2 MNov 10, 2026
52State Board Of Administration Of Florida Retirement System15,124+9,679 (+177.76%)0.27%$2 MNov 13, 2026
53Creative Planning14,717-1,898 (-11.42%)0.26%$2 MNov 2, 2026
54BNP Paribas Financial Markets13,989+13,000 (+1314.46%)0.25%$2 MNov 12, 2026
55Nuveen, LLC13,836-60 (-0.43%)0.25%$2 MNov 10, 2026
56UBS Group AG13,064+5,291 (+68.07%)0.23%$2 MNov 10, 2026
57Royal Bank Of Canada12,115-2,688 (-18.16%)0.22%$2 MNov 16, 2026
58Wells Fargo & Company/mn11,023-3,363 (-23.38%)0.20%$1 MNov 16, 2026
59Invesco Ltd.10,956-906 (-7.64%)0.19%$1 MNov 12, 2026
60Globeflex Capital L P10,838-743 (-6.42%)0.19%$1 MNov 16, 2026
61Martingale Asset Management L P10,828New0.19%$1 MNov 12, 2026
62Stifel Financial Corp9,977-1,225 (-10.94%)0.18%$1 MNov 12, 2026
63Franklin Templeton Inc9,911-11,994 (-54.75%)0.18%$1 MNov 12, 2026
64Envestnet Asset Management Inc8,681-135 (-1.53%)0.15%$1 MNov 16, 2026
65Quantinno Capital Management LP8,368+1,301 (+18.41%)0.15%$1 MNov 13, 2026
66GAMCO Investors, Inc. Et Al8,3400 (0.00%)0.15%$1 MNov 12, 2026
67Evolve Private Wealth, LLC7,976New0.14%$1 MNov 13, 2026
68B. Metzler seel. Sohn & Co. AG7,820New0.14%$1 MOct 30, 2026
69MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.7,583+1,976 (+35.24%)0.13%$1 MNov 16, 2026
70CM Wealth Advisors LLC7,571-770 (-9.23%)0.13%$1 MNov 10, 2026
71Corient Private Wealth LP7,562+5,139 (+212.09%)0.13%$1 MNov 16, 2026
72Monimus Capital Management, LP6,945-48,399 (-87.45%)0.12%$1 MNov 16, 2026
73Jpmorgan Chase & Co6,868+2,919 (+73.92%)0.12%$1 MNov 12, 2026
74Rhumbline Advisers6,674+114 (+1.74%)0.12%$1 MNov 10, 2026
75Mariner, LLC6,559-7,848 (-54.47%)0.12%$1 MNov 12, 2026
76Vident Advisory, LLC6,528-1,080 (-14.20%)0.12%$1 MNov 16, 2026
77Alliancebernstein L.P.6,5000 (0.00%)0.12%$1 MNov 16, 2026
78Empirical Financial Services, LLC d.b.a. Empirical Wealth Management6,455New0.11%$1 MOct 27, 2026
79Cerity Partners LLC5,940-1,473 (-19.87%)0.11%$1 MNov 13, 2026
80CenterBook Partners LP5,756-1,983 (-25.62%)0.10%$1 MNov 2, 2026
81LPL Financial LLC5,623-421 (-6.97%)0.10%$1 MNov 6, 2026
82SEI Investments Co5,372-1,387 (-20.52%)0.10%$1 MNov 10, 2026
83Mercer Global Advisors Inc /adv5,027-1,729 (-25.59%)0.09%$1 MNov 16, 2026
84Thrivent Financial for Lutherans4,867New0.09%$1 MNov 5, 2026
85Deutsche Bank AG\4,728-652 (-12.12%)0.08%$1 MNov 6, 2026
86Price T Rowe Associates Inc /MD/4,3930 (0.00%)0.08%$1 MNov 16, 2026
87Citadel Advisors LLC4,278-31,612 (-88.08%)0.08%$1 MNov 16, 2026
88Bank Of Nova Scotia4,091New0.07%$1 MNov 13, 2026
89Gotham Asset Management, LLC4,070New0.07%$1 MNov 16, 2026
90Quantbot Technologies LP3,891+3,827 (+5979.69%)0.07%$1 MNov 12, 2026
91Boston Partners3,783-261,366 (-98.57%)0.07%$0 MNov 10, 2026
92Keybank National Association/oh3,755New0.07%$0 MNov 4, 2026
93Wealth Enhancement Advisory Services, LLC3,624-651 (-15.23%)0.06%$0 MOct 13, 2026
94Vanguard Global Advisers, LLC3,330+1,338 (+67.17%)0.06%$0 MNov 13, 2026
95Canada Pension Plan Investment Board3,300-3,000 (-47.62%)0.06%$0 MNov 16, 2026
96Seizert Capital Partners, LLC3,227-219 (-6.36%)0.06%$0 MOct 30, 2026
97MetLife Investment Management, LLC3,0940 (0.00%)0.06%$0 MNov 16, 2026
98Glenmede Trust Co NA3,010New0.05%$0 MNov 16, 2026
99Prelude Capital Management, LLC2,984-157 (-5.00%)0.05%$0 MNov 16, 2026
100Caxton Associates LLP2,879New0.05%$0 MNov 13, 2026

All 184 institutional investors, with who bought and sold →

Mutual funds holding Mesa Laboratories, Inc.#

157 funds hold shares worth $176 M (about 31.3% of the company). Since their previous reports 74 added shares and 34 sold, buying $16 M net.
Mutual funds holding Mesa Laboratories, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.168,511$17 M3.0%<0.01%+2.6%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors138,875$14 M2.5%0.02%+9.1%Jun 30, 2026
🇺🇸 Diamond Hill Small Cap FundDiamond Hill Capital Management, Inc.109,454$11 M1.9%3.5%−2.9%Jun 30, 2026
🇺🇸 Column Small Cap Select FundTrust for Professional Managers87,923$9 M1.6%0.47%+27%May 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC74,048$7 M1.3%0.13%+1353%Jun 30, 2026
🇺🇸 Crawford Small Cap Dividend FundCrawford Investment Counsel Inc65,070$6 M1.2%1.7%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.62,568$6 M1.1%<0.01%−0.4%Jun 30, 2026
🇺🇸 Wasatch Micro Cap Value FundWasatch Advisors LP62,487$6 M1.1%1.6%+160%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC58,440$6 M1.0%0.02%+12%Jul 31, 2026
🇺🇸 Keeley Gabelli Small Cap Dividend FundGabelli Funds, LLC53,974$5 M0.96%1.9%no changeJun 30, 2026
🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP53,188$5 M0.95%0.20%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors50,244$5 M0.89%0.03%+16%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC42,724$4 M0.76%0.04%+4101%Jun 30, 2026
🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP42,575$4 M0.76%0.47%−36%Jun 30, 2026
🇺🇸 WPG Partners Select Small Cap Value FundRBB Fund, Inc.34,829$4 M0.62%1.5%+28%May 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC31,118$3 M0.55%0.32%−19%Jul 31, 2026
🇺🇸 Janus Henderson Small Cap Growth Alpha ETFJanus Henderson Investors US LLC30,109$3 M0.54%0.84%+69%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC28,769$3 M0.51%<0.01%−19%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.27,018$3 M0.48%0.02%+3.4%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.26,518$3 M0.47%0.01%−0.8%May 31, 2026
🇺🇸 WisdomTree U.S. SmallCap Dividend FundWisdomTree Asset Management, Inc.24,683$2 M0.44%0.11%+1.7%Jun 30, 2026
🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP22,290$2 M0.40%0.02%+38%Jul 31, 2026
🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP21,544$2 M0.38%0.01%+24%Jul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP18,722$2 M0.33%<0.01%+7.0%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP18,417$2 M0.33%0.02%+4.0%Jul 31, 2026
🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP17,948$2 M0.32%0.42%−42%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.16,440$2 M0.29%<0.01%−0.8%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP15,672$2 M0.28%0.01%−14%Jul 31, 2026
🇺🇸 Virtus NFJ Small-Cap Value FundVirtus Investment Advisers, LLC13,169$1 M0.23%0.51%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.12,958$1 M0.23%0.02%+12%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC13,092$1 M0.23%0.19%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust12,718$1 M0.23%0.05%−0.1%May 31, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC12,920$1 M0.23%1.1%—Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP11,543$1 M0.21%<0.01%+61%Jul 31, 2026
🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC11,527$1 M0.21%0.05%+7.7%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC10,085$1 M0.18%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC10,139$1 M0.18%0.02%+14%Jun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors9,814$1 M0.17%0.02%+7.6%Jul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC8,763$1 M0.16%0.03%−1.6%Jul 31, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC8,657$1 M0.15%0.34%+108%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,428$1 M0.15%<0.01%+4.6%May 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC8,137$1 M0.14%0.33%−12%Jun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.7,490$1 M0.13%<0.01%no changeJul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors7,364$1 M0.13%<0.01%+3.8%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC7,149$1 M0.13%0.02%+15%Jul 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.6,958$1 M0.12%0.07%−11%May 31, 2026
🇺🇸 Gabelli Dividend & Income TrustGabelli Funds, LLC7,100$1 M0.13%0.02%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC5,991$1 M0.11%0.02%+14%Jun 30, 2026
🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc.5,979$1 M0.11%0.08%−2.6%Jun 30, 2026
🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP5,915$1 M0.11%0.42%—Jun 30, 2026
🇺🇸 State Street Institutional Small-Cap Equity FundSSGA Funds Management, Inc.5,756$1 M0.10%0.11%−4.6%Jun 30, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.5,629$1 M0.10%0.02%newJun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP5,500$1 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 Putnam Dynamic Asset Allocation Growth FundFranklin Advisers, Inc.5,486$1 M0.10%0.01%no changeJun 30, 2026
🇺🇸 Vanguard U.S. Quality Factor ETFThe Vanguard Group, Inc.5,133$1 M0.09%0.11%−0.4%May 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.4,907$1 M0.09%0.03%+2.5%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC5,016$0 M0.09%0.03%+26%Jun 30, 2026
🇺🇸 Small Cap Dividend FundAmerican Century Investment Management, Inc.4,835$0 M0.09%0.44%—Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.4,652$0 M0.08%<0.01%no changeJul 31, 2026
🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc.4,588$0 M0.08%0.07%−38%Jul 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.4,444$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Putnam Dynamic Asset Allocation Balanced FundFranklin Advisers, Inc.3,792$0 M0.07%0.01%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC3,607$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,500$0 M0.06%0.02%+52%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation3,430$0 M0.06%0.02%−5.5%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,105$0 M0.06%<0.01%+5.8%May 31, 2026
🇺🇸 State Street SPDR US Small Cap Low Volatility Index ETFSSGA Funds Management, Inc.3,161$0 M0.06%0.12%+16%Jun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP3,066$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC3,003$0 M0.05%<0.01%+3.1%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.2,882$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.2,715$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.2,698$0 M0.05%0.02%+18%Jun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP2,622$0 M0.05%<0.01%+19%Jul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC2,558$0 M0.05%0.02%+14%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,400$0 M0.04%0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC2,040$0 M0.04%<0.01%+4.0%Jul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company1,981$0 M0.04%0.01%−12%May 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC1,799$0 M0.03%0.02%+17%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.1,798$0 M0.03%<0.01%−5.3%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC1,730$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP1,639$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP1,599$0 M0.03%<0.01%+59%Jul 31, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS1,549$0 M0.03%0.07%no changeJun 30, 2026
🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP1,486$0 M0.03%0.02%+17%Jul 31, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.1,481$0 M0.03%0.06%no changeJun 30, 2026
🇺🇸 U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP1,418$0 M0.03%0.02%+6.9%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC1,407$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors1,389$0 M0.02%<0.01%−1.0%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.1,269$0 M0.02%0.03%−4.0%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION1,100$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC1,116$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS1,114$0 M0.02%0.02%no changeJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC1,099$0 M0.02%0.02%+14%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC869$0 M0.02%0.02%+3.9%Jul 31, 2026
🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC873$0 M0.02%0.05%+66%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.842$0 M0.01%0.02%+13%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC808$0 M0.01%0.02%+7.9%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.806$0 M0.01%0.02%+17%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC769$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Small Cap Growth PortfolioDimensional Fund Advisors LP714$0 M0.01%<0.01%+2.0%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Mesa Laboratories, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.4 M
5 purchases, 4 insiders
Sold, 12 months
$1.6 M
7 sales, 4 insiders
Net, 12 months
-$216 K
open market only
Insiders on file
26
since
$902 K-$2.6 M$0Dec 2023: bought $0 (0 trades), sold $169 K (1 trades)Dec 23Sep 2024: bought $0 (0 trades), sold $187 K (1 trades)SepOct 2024: bought $0 (0 trades), sold $572 K (2 trades)OctMar 2025: bought $0 (0 trades), sold $2.6 M (1 trades)MarJun 2025: bought $0 (0 trades), sold $297 K (3 trades)JunMar 2026: bought $452 K (3 trades), sold $0 (0 trades)MarJun 2026: bought $0 (0 trades), sold $770 K (6 trades)JunAug 2026: bought $902 K (2 trades), sold $800 K (1 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Mesa Laboratories, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John James SullivanDirectorGift-1,200——19,418Form 4
filed Shiraz Shabanali LadiwalaDirectorOption exercise+3,810——12,333Form 4
filed Jennifer Sadie AlltoftDirectorOption exercise+2,784——7,662Form 4
filed John James SullivanDirectorOption exercise+2,784——20,618Form 4
filed R. Tony TripenyDirectorOption exercise+2,784——9,082Form 4
filed Shannon HallDirectorOption exercise+2,784——6,973Form 4
filed Mark Christopher CaponeDirectorOption exercise+2,784——6,213Form 4
filed Siddhartha KadiaPresident and CEOBuyindirect+7,093$112.80$800 K7,093Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Ownership and subsidiaries

Source: GLEIF
Mesa Laboratories, Inc. directly owns 1 registered entity:

Markets and events: Mesa Laboratories, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
377,163
6.8% of shares · 4.68 days to cover
Dividend per share, Q3 2026
$0.160
0.0% on a year earlier
Buybacks, Q1 2014
$0M
Q4 2014
Shares sold short, last 24 reportsAll stocks →
Mesa Laboratories, Inc. dividends per share by quarter
Dividend, quarterPer share
Q3 2026$0.160
Q2 2026$0.160
Q1 2026$0.160from the annual figure
Q4 2025$0.160
Q3 2025$0.160
Q2 2025$0.160
Q1 2025$0.160from the annual figure
Q4 2024$0.160
Q3 2024$0.160
Q2 2024$0.160
Q1 2024$0.160from the annual figure
Q4 2023$0.160
Q3 2023$0.160
Q2 2023$0.160
Q1 2023$0.160from the annual figure
Q4 2022$0.160
Q3 2022$0.160
Q2 2022$0.160
Q1 2022$0.160from the annual figure
Q4 2021$0.160
Q3 2021$0.160
Q2 2021$0.160
Q1 2021$0.160from the annual figure
Q4 2020$0.160
Q3 2020$0.160
Q2 2020$0.160
Q4 2019$0.640
Q3 2019$0.160
Q2 2019$0.160
Q1 2013$0.140
Q4 2012$0.140
Q3 2012$0.130
Q2 2012$0.130
Q1 2012$0.130
Q4 2011$0.130
Q3 2011$0.120
Q2 2011$0.120
Q1 2011$0.120
Q4 2010$0.120
Q3 2010$0.110
Mesa Laboratories, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2014Q4 2014$0M
Q4 2013Q3 2013$0M
Q3 2013Q2 2013$0M
Q2 2013Q1 2013$0M
Q1 2013Q4 2012$0M
Q4 2012Q3 2012$0M
Q3 2012Q2 2012$0M
Q2 2012Q1 2012$0M
Q1 2012Q4 2011$0.5M
Q3 2011Q2 2011$0.1M
Q2 2011Q1 2011$0M
Q1 2011Q4 2011$0M
Q4 2010Q3 2011$0M
Q3 2010Q2 2011$0.1M
Q2 2010Q1 2011$0M

Fails to deliver

  • : 336 shares at $129.25
  • : 173 shares at $123.31
  • : 246 shares at $133.01
  • : 11 shares at $127.14
  • : 5,200 shares at $130.65

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Mesa Laboratories, Inc. scorecard#

Passes 16 of the 29 checks that could be worked out: strongest in growth (5 of 6), weakest in valuation (2 of 6). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation2 of 6
    • ✗P/E below its peers' median109.1×P/E 109.1× against Scientific Technical Instruments's median of 32.5×.
    • ✗Price to book below its peers' median3.9×Price to book 3.9× against Scientific Technical Instruments's median of 3.8×.
    • ✓Price to sales below its peers' median2.9×Price to sales 2.9× against Scientific Technical Instruments's median of 4.7×.
    • ✓Free cash flow yield above 5%5.5%Free cash flow is 5.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yield0.9%Earnings yield 0.9% against the 10-year Treasury's 5.15% on 2026-11-13.
    • ✗The price assumes slower growth than the last three years'7.0%The price assumes 7.0% a year for ten years; revenue grew 4.4% a year over the last three.
  • Growth5 of 6
    • ✓Revenue grew in the newest year3.4%Revenue up 3.4% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years4.4%4.4% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median4.4%4.4% a year against Scientific Technical Instruments's median of 3.0% (24 companies).
    • ✓Earnings per share grew in the newest year1.21 vs -0.36Diluted EPS 1.21 in fiscal 2025 against -0.36 the year before (report's currency).
    • ✓Net income higher than five years earlier$7 M$7 M in fiscal 2025 against $3 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability2 of 6
    • ✓Profitable in the newest year$7 MNet income $7 M in fiscal 2025.
    • ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median7.4%7.4% against Scientific Technical Instruments's median of 9.1% (26 companies).
    • ✗Return on equity above 15%3.9%3.9% in fiscal 2025.
    • ✗Return on invested capital above 10%4.8%4.8% in fiscal 2025.
    • ✓Operating margin wider than three years earlier7.4%7.4% in fiscal 2025 against 1.5% in 2022.
  • Financial health4 of 5
    • ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.72 at the end of fiscal 2025.
    • ✓Debt below equity0.4×Debt to equity 0.36 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times1.7×Operating income 1.7 times interest in fiscal 2025.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone2.05Z-score 2.05 (grey zone) for fiscal 2025.
  • Shareholder returns3 of 6
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
    • ✓Dividends under 75% of net income52.5%Dividends were 52.5% of net income in fiscal 2025.
    • ✗Share count up no more than 2% in a year2.7%Diluted shares up 2.7% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value0.5%Dividends and buybacks were 0.5% of the market value.
    • ✓Free cash flow covers dividends and buybacks$40 MFree cash flow $40 M against $4 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Scientific Technical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Mesa Laboratories, Inc.'s statements, beside the median of Scientific Technical Instruments.

Mesa Laboratories, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin7.4%9.1%
Net margin2.7%8.7%
Return on equity3.9%3.9%
Revenue growth, 3 years a year4.4%3.0%
Revenue growth3.4%4.0%
Debt to equity0.36×0.32×

8of 9on the Piotroski tests of financial strength

  • Operating income covers the interest bill only 1.7 times.
  • Goodwill and intangibles ($270 million) exceed shareholders' equity ($186 million).
  • Free cash flow has been positive 9 years in a row.

Mesa Laboratories, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Mesa Laboratories, Inc.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026FY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Mar 31, 2022FY 2020to Mar 31, 2021FY 2019to Mar 31, 2020FY 2018to Mar 31, 2019FY 2017to Mar 31, 2018FY 2016to Mar 31, 2017
Income statement
Revenue2492412162191841341181039694
Cost of revenue91908385754752r424240
Gross profit1581511331341098765r615553
Research and development2020192016106.43.53.54.2
Selling and marketing414239372818138.38.810.0
General and administrative797373726046r38r312623
Operating expenses1401354051301047557515237
Operating income1916−2723.34.7127.9r9.82.216
Interest and finance income—————0.11.00.00.0—
Interest expense and finance costs11125.74.83.98.05.51.71.9—
Other non-operating income (expense)−6.5−10−3.6−3.7−1.1−10−4.1−1.2−1.9−2.0
Income before tax126.0−276−0.43.62.33.9r8.60.314
Income tax5.37.9−21−1.31.7−1.02.11.13.33.1
Income from continuing operations126.0−276−0.4——————
Net income attributable to shareholders6.7−2.0−2540.91.93.3————
Earnings per share, basic1.22-0.36-47.200.170.360.660.42r1.95-0.793.04
Earnings per share, diluted1.21-0.36-47.200.170.350.640.41r1.86-0.792.91
Shares, weighted average (basic)5.55.45.45.35.25.04.23.83.83.7
Shares, weighted average (diluted)5.65.45.45.45.35.14.44.03.83.8
Dividends per share0.640.640.640.640.640.640.640.64——
Balance sheet
Cash and cash equivalents272728334926481105.55.8
Receivables44423943412421131414
Inventory26253335251111r6.89.214
Other current assets3.62.93.34.0r2.3r4.9r1.9r1.60.81.2r
Current assets106103109119124304123343236
Property, plant and equipment31323228292222222426
Right-of-use (leased) assets18169.78.7——————
Goodwill187182180286291161142666672
Other intangible assets8397114217250112120334338
Total assets428433447662707601409r157164172
Accounts payable4.95.76.06.17.94.53.42.92.42.2
Debt due within a year———————2.11.61.1
Current liabilities621644443483326241717
Long-term debt———————214554
Lease liabilities (non-current)14126.65.8——————
Total liabilities242274301268314195189r456574
Retained earnings−186−189−18374777272r736874
Shareholders' equity1861601453933944062201119998
Total liabilities and equity428433447662707601409r157164172
Shares outstanding5.55.55.45.45.35.14.43.93.83.7r
Cash-flow statement
Depreciation and amortization———342518139.49.58.7
Share-based compensation18131213119.35.54.21.71.4
Cash from operating activities43474428393727r3126r17r
Capital expenditure−3.3−4.2−2.6−4.5−4.4−2.0−1.5−1.3−2.8—
Intangible assets bought0−0.300——————
Acquisitions, net of cash acquired00−79−5.0−3010−184−4.8−16−8.6
Cash from investing activities−3.3−4.5−81−9.5−305−2.0−186−3.9−17−18
Debt repaid−37−44−34−36−210−23−26−20−57
Shares issued———00146850——
Dividends paid−3.5−3.5−3.4−3.4−3.3−3.2−2.7−2.5−2.4−2.4
Cash from financing activities−42−4533−3353146231−22−9.0r1.2r
Change in cash−0.4−0.9−4.7−16−215182714.7−0.40.1
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Mesa Laboratories, Inc. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$203 M82%
  • Consumables$146 M59%
  • Hardware and Software$57 M23%
  • Service(total)$46 M18%

Business segments

  • Sterilization and Disinfection Control$102 M41%
  • Calibration Solutions$54 M22%
  • Biopharmaceutical Development$49 M20%
  • Clinical Genomics$45 M18%

Countries and regions

Source: SEC annual report (XBRL data) · as of Mar 31, 2026

Where Mesa Laboratories, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Mesa Laboratories, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office$117 M47%
🇫🇷 France1 subsidiary—
🇨🇳 China$20 M8.2%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Mesa Laboratories, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$6.6 M
Siddhartha Kadia
Other top executives, average
$2.3 M
the CEO earned 2.9× this
$100 invested is now
$37
peer group: $35
Mesa Laboratories, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Siddhartha Kadia$6.6 M$516 K$2.3 M$37 (peers $35)
2025Siddhartha Kadia$6.6 M$7.9 M$2.3 M$50 (peers $33)
2024Siddhartha Kadia$5.4 M$78 K$1.8 M$46 (peers $43)
2023Siddhartha Kadia$5.2 M−$3.6 M$1.5 M$72 (peers $46)
2022Siddhartha Kadia$18.1 M$16.8 M$1.5 M$105 (peers $66)

Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026

Events at Mesa Laboratories, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • ImpairmentFiling

Auditor changed 2 · Impairment 1 · Restructuring 1 · Directors and officers 3 · Material agreement 1 · New debt 1 · Shareholder vote 3 · Results announced 12

Mesa Laboratories, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Restructuring8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
New debt8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Impairment8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

H-1B hiring at Mesa Laboratories, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $169 K a year.

Certified, FY2026
1
#1,803 among companies on value.today
Worker positions
1
Median wage offered
$169 K
a year, full-time
Applications filed
1
Mesa Laboratories, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Manager, Product Management Calibration SolutionsBioengineers and Biomedical Engineers1$169 K

Where: Lakewood, CO 1

Mesa Laboratories, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$169 K1
FY202311$160 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Mesa Laboratories, Inc.

Product recalls by Mesa Laboratories, Inc.#

2 recalls since 2015, 10,228 units in the notices that give a number. Medical devices (FDA): 2.

Mesa Laboratories, Inc.: product recalls
DateWhat and whyUnitsNotice
MesaLabs Conductivity Standard Solution, 14 mS/cm, 32 ounces (950 ml). Product No. : 02.0027, 020510 (carton of 6 of 02.0027). Polyethylene bottle Conductivity/TDS Calibrator solutions are a secondary standard solution used for the calibration of conductivity/TDS cells together with conductivity/TDS measurement instruments. The…Mesa Laboratories is recalling Conductivity/TDS Calibrator Solution due to failure to meet product specifications.Medical devicesClass II9,900Z-2159-2017
ProSpore 4 mL Ampoule Biological indicator for steam sterilization, contains Geobacillus stearothermophilus, Catalog Number: PS-6-50, contains 50 Ampoules/Box. Product Usage: Biological indicator for steam sterilization at 121 deg C intended for use by a health care provider to accompany products being sterilized through steam…Product resistance has fallen outside of label claim within expiry.Medical devicesClass II328Z-1104-2017

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Layoffs at Mesa Laboratories, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
40
1 notices and filings
People, all years
40
2026–2026
Latest
40 people
2026-10-12
Mesa Laboratories, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026·········40·40
Mesa Laboratories, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
40 peopleRestructuring planSEC 8-K“The Restructuring Program includes the elimination of approximately 40 positions, primarily in our Clinical Genomics division, with additional reductions in our corporate functions…”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Mesa Laboratories, Inc.#

4 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 9 November 2026automatic update · Nov 9, 2026

    Mesa Laboratories, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $62 million (up 3% from a year earlier) and net income of $4 million (up 75% from a year earlier).

  • Reported to the SEC: Restructuringautomatic update · Oct 13, 2026

    Mesa Laboratories, Inc. reported on 13 October 2026 (SEC Form 8-K): • Restructuring: A plan to exit or dispose of activities, usually with job cuts. This is the SEC's classification of the filing; the filing itself has the details.

  • Layoff notice: 40 peopleautomatic update · Oct 12, 2026

    A restructuring plan at Mesa Laboratories, Inc. was announced on 12 October 2026: 40 people affected. Source: SEC filing (8-K Item 2.05).

How Mesa Laboratories, Inc. compares in Scientific Technical Instruments

  • Market cap$726 M · higher than 36% of 87
  • Revenue$249 M · higher than 38% of 64
  • Net margin2.6% · higher than 29% of 60
  • Revenue growth3.4% · higher than 47% of 37
  • P/E ratio109.1× · lower than 3% of 33
  • Price / sales2.9× · lower than 70% of 44
  • Price / book3.9× · lower than 54% of 42
  • FCF yield5.5% · higher than 87% of 24

Peer comparison · Scientific Technical Instruments

CompanyMarket capP/ENet marginRev. growth
Mesa Laboratories, Inc.🇺🇸$726 M109.1×2.6%+3.4%
Keyence Corporation🇯🇵$134.1 B44.5×38.1%—
Keysight Technologies, Inc.🇺🇸$64.3 B51.0×19.1%+8.0%
Garmin Ltd.🇺🇸$54.9 B27.2×25.6%+15.1%
Coherent Corp.🇺🇸$41.2 B42.8×12.2%+22.5%
Hexagon AB (publ)🇸🇪$32.8 B44.9×11.4%—
Teledyne Technologies Incorporated🇺🇸$28.0 B27.3×15.8%+7.9%
MKS Instruments, Inc.🇺🇸$21.0 B71.2×7.5%—
Lasertec Corporation🇯🇵$19.8 B34.5×33.7%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Employees:
As on June-2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Mesa Laboratories, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Mesa Laboratories, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Mesa Laboratories, Inc.? Suggest a correction